Epsilon M&A Deal Report - Apperton

Transaction Multiples for the Valuation of Private Companies

Private group led by Evolem, Garibaldi Participations, BNP Paribas Développement > Apperton

Announced Date : 16 September 2025

Type : SBO (Secondary Buy Out) ,Exit

Deal Value : Yes

Acquirer : Private group led by Evolem, Garibaldi Participations, BNP Paribas Développement

Target: Apperton

Target Country: France

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Formed from the 2019 merger of Stérience and Vanguard France, Apperton is the French lea ...

No EMAT : 124351

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating *

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1297

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
09/11/2023	Private group led by Eurazeo	Enies (Ex Nihilo)	France	**
24/12/2020	Colosseum Dental Group (CDG)	Dentelia	France	*

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database